Oncopeptides AB (publ) (ONCO) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncopeptides Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.597 Welcome to Oncopeptide's Q2 Earnings Call for 2025. 00:00:03.597 -- 00:00:09.007 For the first part of the conference call, the participants will be in listen-only mode. 00:00:09.007 -- 00:00:13.675 During the questions and answers session, participants are able to ask questions by dialing 00:00:13.675 -- 00:00:18.744 pound key 5 on their telephone keypad. Now I will hand the conference over to CEO 00:00:18.744 -- 00:00:24.365 Sophia Higas and CFO Henrik Bergentoft. Please go ahead. 00:00:24.365 -- 00:00:29.912 Hi everyone and welcome to the presentation of Oncopeptides report for the second quarter 00:00:29.912 -- 00:00:34.777 of 2025. This is our standard disclaimer. 00:00:34.777 -- 00:00:39.803 I'm Sofia Hegis, CEO of Oncopeptides and I'm joined by our CFO Henrik 00:00:39.803 -- 00:00:43.968 Bergentoft who will give a financial update in just a few minutes. 00:00:43.968 -- 00:00:47.653 Let's start with the highlights from the quarter. 00:00:47.653 -- 00:00:52.934 Q2 was an eventful quarter and we took strong steps forward in Europe. 00:00:52.934 -- 00:00:58.482 We reached net sales of 19.2 million SEK. That's up 45% 00:00:58.482 -- 00:01:04.311 compared to Q1 and 135% versus last year. It's 00:01:04.311 -- 00:01:10.349 worth to point out that this is our third quarter in a row with more than 30% growth. 00:01:10.349 -- 00:01:15.558 Germany continues to perform well. Spain and Italy has been moving faster than 00:01:15.558 -- 00:01:20.887 expected on regional access and the positive clinical experience generated has 00:01:20.887 -- 00:01:25.936 already now been translated into real world publications that is supporting our 00:01:25.936 -- 00:01:27.599 launches. 00:01:27.599 -- 00:01:32.627 Momentum has carried into the summer too...